Bambusa Therapeutics, Inc. SEC filings BBTX
Bambusa Therapeutics, Inc. has 29 filings in SEC EDGAR's recent list, going back to Jan 8, 2025. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B4 | Prospectus | Oct 30, 2026 | — |
| S-8 | Employee stock plan registration | Oct 30, 2026 | — |
| S-1MEF | Filing | Oct 29, 2026 | — |
| S-1/A | Amended registration statement | Oct 26, 2026 | — |
| S-1 | Registration statement | Oct 9, 2026 | — |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BBTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC CIK
- 2044950
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.